146 related articles for article (PubMed ID: 36167530)
21. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
23. Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma.
Song Z; Cai Z; Yan J; Shao YW; Zhang Y
Transl Lung Cancer Res; 2019 Aug; 8(4):392-400. PubMed ID: 31555514
[TBL] [Abstract][Full Text] [Related]
24. Comparison of genomic profiling of circulating tumor DNA in pancreaticobiliary malignancies in plasma and bile.
Ohyama H; Hirotsu Y; Amemiya K; Miura Y; Hirose S; Oyama T; Iimuro Y; Kojima Y; Mikata R; Mochizuki H; Kato N; Omata M
Cancer; 2023 Jun; 129(11):1714-1722. PubMed ID: 36932987
[TBL] [Abstract][Full Text] [Related]
25. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
26. Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens.
Liu L; Shao D; Deng Q; Tang H; Wang J; Liu J; Guo F; Lin Y; Peng Z; Mao M; Kristiansen K; Ye M; He J
J Thorac Dis; 2018 May; 10(5):2631-2637. PubMed ID: 29997924
[TBL] [Abstract][Full Text] [Related]
27. Targeted deep sequencing from multiple sources demonstrates increased NOTCH1 alterations in lung cancer patient plasma.
Liao Y; Ma Z; Zhang Y; Li D; Lv D; Chen Z; Li P; Ai-Dherasi A; Zheng F; Tian J; Zou K; Wang Y; Wang D; Cordova M; Zhou H; Li X; Liu D; Yu R; Zhang Q; Zhang X; Zhang J; Zhang X; Zhang X; Li Y; Shao Y; Song L; Liu R; Wang Y; Sufiyan S; Liu Q; Owen GI; Li Z; Chen J
Cancer Med; 2019 Sep; 8(12):5673-5686. PubMed ID: 31369215
[TBL] [Abstract][Full Text] [Related]
28. A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients.
Kawahara A; Fukumitsu C; Azuma K; Taira T; Abe H; Takase Y; Murata K; Sadashima E; Hattori S; Naito Y; Akiba J
Cytopathology; 2018 Apr; 29(2):150-155. PubMed ID: 29363841
[TBL] [Abstract][Full Text] [Related]
29. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
Song Z; Wang W; Li M; Liu J; Zhang Y
Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
[TBL] [Abstract][Full Text] [Related]
30. [Current situation and prospect of breast cancer liquid biopsy].
Zhou B; Xin L; Xu L; Ye JM; Liu YH
Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):106-109. PubMed ID: 29397622
[TBL] [Abstract][Full Text] [Related]
31. Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination.
Yamashita K; Kuba T; Shinoda H; Takahashi E; Okayasu I
Am J Clin Pathol; 1998 Jun; 109(6):704-11. PubMed ID: 9620027
[TBL] [Abstract][Full Text] [Related]
32. Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology.
Yang SR; Mooney KL; Libiran P; Jones CD; Joshi R; Lau HD; Stehr H; Berry GJ; Zehnder JL; Long SR; Kong CS; Kunder CA
Cancer Cytopathol; 2020 Jan; 128(1):43-56. PubMed ID: 31751001
[TBL] [Abstract][Full Text] [Related]
33. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
[TBL] [Abstract][Full Text] [Related]
34. Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data.
Zhao S; Cong X; Liu Z
Biomed Res Int; 2021; 2021():8817898. PubMed ID: 33997043
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
36. Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?
Pittella-Silva F; Chin YM; Chan HT; Nagayama S; Miyauchi E; Low SK; Nakamura Y
Clin Chem; 2020 Jul; 66(7):946-957. PubMed ID: 32516802
[TBL] [Abstract][Full Text] [Related]
37. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y
Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963
[TBL] [Abstract][Full Text] [Related]
38. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
39. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
[TBL] [Abstract][Full Text] [Related]
40. Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.
Yu J; Cho E; Choi J; Lim JE; Lee J; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
Investig Clin Urol; 2021 Mar; 62(2):224-232. PubMed ID: 33660451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
